Stem is trading 10.34% down at $2.70; no fresh company announcement explaining the October 27 decline was identified.
- On October 26, Stem announced a strategic-alternatives review, including a possible sale or merger, with no timetable or assurance of a transaction; it does not establish a cause.
- The broader market was positive, so the decline ran against its direction.
- Stem disclosed NYSE listing-standard noncompliance on October 23; this is prior news, not a confirmed cause of the move.